A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)

Taiho Pharmaceutical Co., Ltd.0 个研究点目标入组 594 人开始时间: 2016年8月22日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Taiho Pharmaceutical Co., Ltd.
入组人数: 594

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

FosNTP 235 mg group showed superior prevention of chemotherapy-induced nausea and vomiting among patients receiving cisplatin-based chemotherapy compared with the placebo group, and with a satisfactory safety profile.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•Patients who are scheduled to receive cancer chemotherapy including the HEC agents
•- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1
•- Patients who have provided written informed consent

排除标准

•- Patients with infection, diabetes mellitus, or other disease to whom it difficult to administer of DEX, which is defined in the protocol
•- Patients who are unable or unwilling to cooperate in the implementation of study procedures

研究者

发起方

Taiho Pharmaceutical Co., Ltd.

相似试验

终止

2 期

Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINVChemotherapy Induced Nausea Vomiting

NCT03008213Joseph Ma4

已完成

4 期

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and VomitingUterine CancerOvarian Cancer

NCT01432015Gynecologic Oncology Associates20

尚未招募

3 期

sing medicine Fosaprepitant along with other anti-vomiting medications for better control of vomiting and nausea in children receiving chemotherapy

CTRI/2023/12/060941Cancer Institute (WIA)

撤回

不适用

Prevention of Unmitigated Chemotherapy-induced EmesisChemotherapy-induced Nausea and VomitingNausea Post Chemotherapy

NCT03996863Otolith Labs

Unknown

3 期

preventing chemotherapy induced nausea and vomiting in children without using steroid (dexamethasone)

CTRI/2022/05/042750Cancer Institute